Champions Oncology Stock (NASDAQ:CSBR)
Previous Close
$4.46
52W Range
$3.60 - $7.13
50D Avg
$4.65
200D Avg
$5.14
Market Cap
$68.65M
Avg Vol (3M)
$40.79K
Beta
0.46
Div Yield
-
CSBR Company Profile
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
CSBR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ANTX | AN2 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| PRDS | Pardes Biosciences, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |